Opioid Use Disorder Treatment Among Medicaid Beneficiaries During Pandemic

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, MARCH 11, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2022.0093?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031122

About JAMA Health Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

What The Study Did: Researchers examined whether Medicaid patients in Wisconsin with opioid use disorder experienced decreased access to treatment, including receiving buprenorphine and urine drug testing during the COVID-19 pandemic.

Authors: Alyssa Shell Tilhou, M.D., Ph.D., of the Boston University School of Medicine/Boston Medical Center, is the corresponding author.

 

(doi:10.1001/jamahealthforum.2022.0093)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.